Phase 1/2 study of RP L102 in the patients with Fanconi's-anaemia

Trial Profile

Phase 1/2 study of RP L102 in the patients with Fanconi's-anaemia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 May 2018

At a glance

  • Drugs RP L102 (Primary)
  • Indications Fanconi's anaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 May 2018 According to a Rocket Pharmaceuticals media release, Julian Sevilla, M.D., Ph.D., of the hospital of Nino Jesus in Madrid, is the principal investigator of this trial. Five patients have been treated to date.
    • 18 May 2018 According to a Rocket Pharmaceuticals media release, data from this trial was presented at the Presidential Symposium at the American Society of Gene and Cell Therapy (ASGCT) annual meeting (2018).
    • 18 May 2018 Results presented in the Rocket Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top